SecBot SecBot
SC 13G/A ·Filed Nov 16, 2026

TLSI

TriSalus Life Sciences, Inc.
NEUTRAL
Impact 3/10
Processed23h 39m ago SEC0001999371-26-025526
Passive stake amendment

Price Chart

Loading chart...

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001999371-26-025526
Document: 0001999371-26-025526-index-headers.html0001999371-26-025526
Document: 0001999371-26-025526-index.html0001999371-26-025526
Document: 0001999371-26-025526.txt0001999371-26-025526

Track record

7 reports on TLSI

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +37.36% at T+60 after the Jun 11, 2026 report. 3 of 3 went positive at some point.

Filters
  1. Nov 17, 2026today Insider Cluster Neutral 3/10 Entry $2.20 Now $2.30 +4.32% settles Nov 19
  2. Nov 16, 2026today SC 13G/A Neutral 3/10 Viewing Entry $2.27 Now $2.30 +1.10% settles Nov 18
  3. Nov 10, 20267d ago 8-K Bearish 6/10 Entry $2.85 to $2.30 Now $2.30 +19.47% ▲ +19.30% +20.62% vs SPY
  4. Jun 11, 202622w ago Institutional Cluster Neutral 2/10 Entry $3.64 to $3.77 Now $2.30 −36.95% ▲ +3.57% +3.03% vs SPY
  5. Jun 11, 202622w ago Institutional Cluster Bullish 4/10 Entry $3.64 to $3.77 Now $2.30 −36.95% ▲ +3.57% +3.03% vs SPY
  6. Mar 11, 202635w ago Insider Cluster Neutral 3/10 Entry $4.16 to $4.10 Now $2.30 −44.83% ▼ −1.44% +0.04% vs SPY
  7. Mar 5, 202636w ago 8-K Bullish 8/10 Entry $4.47 to $4.62 Now $2.30 −48.60% ▲ +3.36% +2.51% vs SPY
Showing 7 of 7

US Market Status

Market Closed · Opens Wed (17h 2m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026

Fresh TLSI Intelligence

Analysis is for subscribers only.

Subscribe for Full Access